Healio: VIDEO: SGLT2 inhibitors may protect organs in acute illness

The DARE-19 trial explored repurposing existing medications to treat COVID-19.

Healio talked to Dr. Mikhail Kosiborod, Vice President of Research at Saint Luke's Health System and the Ben McCallister, MD, Endowed Chair in Cardiovascular Research at Saint Luke's Mid America Heart Institute, about the hypothesis that SGLT2 inhibitors can provide organ protection in acute illness beyond COVID-19.

Watch the full Healio interview: VIDEO: SGLT2 inhibitors may protect organs in acute illness

Related Content

Jun. 28, 2021

Healio: DARE-19: Dapagliflozin well-tolerated for inpatient COVID-19 with, without diabetes
The SGLT2 inhibitor dapagliflozin is well-tolerated in adults hospitalized with COVID-19, regardless of diabetes status, according to new analyses from the DARE-19 trial.
Jun. 11, 2021

HCP Live: The Significance of DAPA-HF for Cardiovascular Care and Beyond
HCP Live talked to Dr. Mikhail Kosiborod about the clinical impact of the DAPA-HF trial. 
May. 20, 2021

Health News You Can Use: How Saint Luke's Research is Changing Patient Care
Actively involved in more than 100 clinical trials aimed to improve patient care, Saint Luke's Research changes lives.